CL 2016/13-FA Annex 2

#### FORM FOR THE SUBMISSION OF SUBSTANCES TO BE EVALUATED BY JECFA

In completing this form, only brief information is required. The form may be retyped if more space is needed under any one heading provided that the general format is maintained.

| Name of Substance(s):                  | Endo-1,4-β-xylanase from <i>Bacillus subtilis</i> produced by <i>B. subtilis</i> LMG S-28356 |
|--|--|
| Question(s) to be answered by<br>JECFA | Safety evaluation when used as a processing aid  |

1. Proposal for inclusion submitted by:

The Belgian Federal Public Service Health, Food Chain Safety and Environment Place Victor Horta 40 box  $10\,$ 

1060 Brussels/Sint-Gillis

Belgium

E-mail: apf.food@health.belgium.be

Name of substance; trade name(s); chemical name(s):

Name: Endo-1,4-β-xylanase from *B. subtilis* produced by *B. subtilis* strain LMG S-28356

IUBMB name: EC 3.2.1.8

Tradename: Bel'Ase B210 / Premix X-600 (Main commercial names)

chemical names:  $4-\beta$ -D-xylan xylanohydrolase; endo- $(1-4)-\beta$ -xylan 4-xylanohydrolase; endo- $(1\rightarrow 4)-\beta$ -

xylan 4-xylanohydrolase; endo-1,4-xylanase; xylanase;  $\beta$ -1,4-xylanase: endo-1,4-xylanase; endo- $\beta$ -1,4-xylanase; endo-1,4- $\beta$ -D-xylanase; 1,4- $\beta$ -xylan xylanohydrolase;

β-xylanase; β-1,4-xylan xylanohydrolase; endo-1,4-β-xylanase; β-D-xylanase

3. Names and addresses of basic producers

Puratos NV- site Beldem

Rue Bourrie 12 B-5300 Andenne

Belgium

Tel. no: +32 8582 3250 Fax no: +32 8582 3260

4. Has the manufacturer made a commitment to provide data?

Puratos NV commits to provide data to support the proposal for the inclusion of Endo-1,4- $\beta$ -xylanase in the list of substances to be evaluated by the JECFA.

5. Identification of the manufacturer that will be providing data (Please indicate contact person):

Name: Puratos NV Address: Industrialaan 25

Postal code and City: B-1702 Groot-Bijgaarden

Country: Belgium

Tel. no: +32 2481 4444

Fax no: +32 2466 2581

Contact person: Bas Verhagen

Tel: +32 2481 4551

E-mail: BVerhagen@puratos.com

6. Justification for use:

The food enzyme catalyses, i.e. accelerates, the conversion of substrate arabinoxylan into products arabinoxylan oligosaccharides.

The transformation of substrate arabinoxylans provides the following benefits, of interest during the production of bakery products:

- Facilitate the handling of the dough
- Improve the dough's structure and behaviour during the baking step
- Ensure a uniform volume and an improved crumb structure of the bakery product
- Reduce batter viscosity
- reduce losses of dough (less stickiness of dough)
- 7. Food products and food categories within the GSFA in which the substance is used as a food additive or as an ingredient, including use level(s)

The enzyme preparation is used as a processing aid during production of bakery products. The food enzyme is denatured during the baking process. Therefore it cannot have any technological function anymore in final baked foods.

Food enzyme preparations are used by food manufacturers according to the *Quantum Satis* principle, which means that food manufacturers will typically fine-tune the enzyme dosage based on a dose range recommended by the enzyme supplier. The recommended dose ranges for this xylanase in baking processes is 2.1-31.5 IU per kg raw material (flour).

8. Is the substance currently used in food that is legally traded in more than one country? (please identify the countries); or, has the substance been approved for use in food in one or more country? (please identify the country(ies))

The use in food of the Endo-1,4- $\beta$ -xylanase from *B. subtilis* produced by *B. subtilis* is officially approved in France; Canada; China; Brazil; Mexico; Australia; Japan.

Moreover, the enzyme is legally traded and the use in food is legal in many countries worldwide, including in the EU.

A new dossier has also been submitted in the EU under Regulation (EC) No 1332/2008, and is currently under review by the EFSA.

Finally, the enzyme endo-1,4-β-xylanase from *B. subtilis* has also been approved in the EU for the use as feed additive under the trade name Belfeed B1100 MP/ML.

9. List of data available (please check, if available)

# Toxicological data

This *B. subtilis* strains is from a safe lineage that has been tested according to the criteria laid out in Pariza and Johnson (2001<sup>1</sup>). The safety of *B. subtilis* as a production microorganism has been assessed by EFSA (2007<sup>2</sup>) and has been accorded Qualified Presumption of Safety (QPS) status. A review of the literature by the US EPA (1997<sup>3</sup>) failed to reveal the production of metabolites of toxicological concern by *B. subtilis*. Nonetheless, to comply with the various regulatory requirements in different countries, several toxicity experiments have been performed.

(i) Metabolic and pharmacokinetic studies

Not applicable

(ii) Short-term toxicity, long-term toxicity/carcinogenicity, reproductive toxicity, and developmental toxicity studies in animals and genotoxicity studies

The food enzyme has been subjected to a standard package of toxicological tests in line with internationally accepted guidelines (OECD/EU), with the following results:

Ames test: No mutagenic activity under the given test conditions
Chromosomal aberrations: No clastogenic activity under the given test conditions

Evaluating the safety of microbial enzyme preparations used in food processing: update for a new century. Regulatory Toxicology and Pharmacology 33:173-186.

Opinion of the Scientific Committee on a request from EFSA on the Introduction of a Qualified Presumption of Safety (QPS) approach for assessment of selected microorganisms referred to EFSA. The EFSA Journal 587, 1-16.

 $<sup>^3\</sup> https://www.epa.gov/sites/production/files/2015-09/documents/fra009.pdf.$ 

Bone marrow micronucleus test: No cytogenetic adverse effects reported under the given

test conditions

90-day oral toxicity on rats: The No Observed Adverse Effect Level (NOAEL) is 140 mg

TOS/kg bw/day, which is the highest dose in the study.

In short, the food enzyme object of the present dossier was subjected to several toxicological studies to confirm its safety for consumers. The mutagenicity studies supported that the food enzyme does not have the potential to damage the genetic material of living organisms, including mammals. The oral toxicity study showed that the food enzyme does not exhibit signs of toxicity, up to doses that are thousand times higher than those which are consumed via food.

(iii) Epidemiological and/or clinical studies and special considerations Not applicable

(iv) Other data

None

## Technological data

(i) Specifications for the identity and purity of the listed substances (specifications applied during development and toxicological studies; proposed specifications for commerce)

The food enzyme xylanase complies with the internationally accepted JECFA specifications for chemical and microbiological purity of food enzymes (FAO/WHO Monographs 3, 2006) and with the French purity criteria of enzymes (AR 19/10/2006). Neither the production strain nor antibiotic resistance genes are present in the final product. Moreover, the no presence of biologically active DNA has been shown.

The endo-1,4- $\beta$ -xylanase described in this dossier is manufactured in accordance with current Good Manufacturing Practice for Food (GMP) and the principals of Hazard Analysis of Critical Control Points (HACCP) and in line with Food Hygiene Regulation (EC) No 852/2004 and Regulation (EC) No 178/2002.

(ii) Technological and nutritional considerations relating to the manufacture and use of the listed substance

Endo-1,4- $\beta$ -xylanase from *B. subtilis* is a protein used at very low dosage. Therefore, it has no nutritional impact on final baked products. The food enzyme is denatured during baking. As other food proteins, the enzyme may be hydrolyzed into its constitutive amino acids. Products of the xylanase hydrolysis are natural constituents of the cereals based foods and no anti nutritional effects could result of the degradation of (arabino)xylans by xylanase food enzyme. Use of endo-1,4- $\beta$ -xylanase from *B. subtilis* in food (baking applications) doesn't alter the nutritional composition nor modify nutritional value of foodstuffs.

### Intake assessment data

(i) Levels of the listed substance used in food or expected to be used in food based on technological function and the range of foods in which they are used

The food enzyme object of this dossier is typically used in the manufacturing of bakery products such as, but not limited to, bread, biscuits, steamed bread, cakes, pancakes, tortillas, wafers and waffles.

Based on the maximum recommended use level for the enzyme per raw material (flour) and the average amount of flour used for baking, the maximum level of TOS in the final food will be 0.143 mg TOS/ kg food.

(ii) Estimation of dietary intakes based on food consumption data for foods in which the substance may be used.

The total Theoretical Maximum Daily Intake (TMDI) can be calculated on basis of the maximal values found in baked foods, multiplied by the maximum consumption of baked foods/kg body

weight/day. Based on the recommended use levels, the amounts of the respective ingredients that end up in the final foods and the amount of produce consumed by the high end consumers, the TMDI of the food enzyme endo-1,4- $\beta$ -xylanase from *B. subtilis* was calculated to be 0.59  $\mu$ g TOS/kg body weight/day.

It should be stressed that this total TMDI is based on conservative assumptions and represents a highly exaggerated value.

# Other information (as necessary/identified)

None

10. Date on which data could be submitted to JECFA.

As soon as required.